Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease

Mielke, Michelle M. ; Anderson, Matthew ; Ashford, J. Wesson ; Jeromin, Andreas ; Lin, Pei Jung ; Rosen, Allyson ; Tyrone, Jamie ; Vandevrede, Lawren ; Willis, Deanna R. and Hansson, Oskar LU orcid , et al. (2024) In Alzheimer's and Dementia 20(11). p.8216-8224
Abstract

Blood-based biomarkers (BBM) for Alzheimer's disease (AD) are being increasingly used in clinical practice to support an AD diagnosis. In contrast to traditional diagnostic modalities, such as amyloid positron emission tomography and cerebrospinal fluid biomarkers, BBMs offer a more accessible and lower cost alternative for AD biomarker testing. Their unique scalability addresses the anticipated surge in demand for biomarker testing with the emergence of disease-modifying treatments (DMTs) that require confirmation of amyloid pathology. To facilitate the uptake of BBMs in clinical practice, The Global CEO Initiative on Alzheimer's Disease convened a BBM Workgroup to provide recommendations for two clinical implementational pathways for... (More)

Blood-based biomarkers (BBM) for Alzheimer's disease (AD) are being increasingly used in clinical practice to support an AD diagnosis. In contrast to traditional diagnostic modalities, such as amyloid positron emission tomography and cerebrospinal fluid biomarkers, BBMs offer a more accessible and lower cost alternative for AD biomarker testing. Their unique scalability addresses the anticipated surge in demand for biomarker testing with the emergence of disease-modifying treatments (DMTs) that require confirmation of amyloid pathology. To facilitate the uptake of BBMs in clinical practice, The Global CEO Initiative on Alzheimer's Disease convened a BBM Workgroup to provide recommendations for two clinical implementational pathways for BBMs: one for current use for triaging and another for future use to confirm amyloid pathology. These pathways provide a standardized diagnostic approach with guidance on interpreting BBM test results. Integrating BBMs into clinical practice will simplify the diagnostic process and facilitate timely access to DMTs for eligible patients.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, amyloid, biomarker, blood-based biomarkers, clinical implementation, clinical practice, cognitive impairment, disease-modifying treatment, patient journey, primary care, secondary care
in
Alzheimer's and Dementia
volume
20
issue
11
pages
9 pages
publisher
Wiley
external identifiers
  • pmid:39351838
  • scopus:85205494218
ISSN
1552-5260
DOI
10.1002/alz.14184
language
English
LU publication?
yes
id
177e4597-7350-4316-9c8d-4ca8c259b93b
date added to LUP
2024-12-18 15:21:35
date last changed
2025-07-03 20:51:10
@article{177e4597-7350-4316-9c8d-4ca8c259b93b,
  abstract     = {{<p>Blood-based biomarkers (BBM) for Alzheimer's disease (AD) are being increasingly used in clinical practice to support an AD diagnosis. In contrast to traditional diagnostic modalities, such as amyloid positron emission tomography and cerebrospinal fluid biomarkers, BBMs offer a more accessible and lower cost alternative for AD biomarker testing. Their unique scalability addresses the anticipated surge in demand for biomarker testing with the emergence of disease-modifying treatments (DMTs) that require confirmation of amyloid pathology. To facilitate the uptake of BBMs in clinical practice, The Global CEO Initiative on Alzheimer's Disease convened a BBM Workgroup to provide recommendations for two clinical implementational pathways for BBMs: one for current use for triaging and another for future use to confirm amyloid pathology. These pathways provide a standardized diagnostic approach with guidance on interpreting BBM test results. Integrating BBMs into clinical practice will simplify the diagnostic process and facilitate timely access to DMTs for eligible patients.</p>}},
  author       = {{Mielke, Michelle M. and Anderson, Matthew and Ashford, J. Wesson and Jeromin, Andreas and Lin, Pei Jung and Rosen, Allyson and Tyrone, Jamie and Vandevrede, Lawren and Willis, Deanna R. and Hansson, Oskar and Khachaturian, Ara S. and Schindler, Suzanne E. and Weiss, Joan and Batrla, Richard and Bozeat, Sasha and Dwyer, John R. and Holzapfel, Drew and Jones, Daryl Rhys and Murray, James F. and Partrick, Katherine A. and Scholler, Emily and Vradenburg, George and Young, Dylan and Braunstein, Joel B. and Burnham, Samantha C. and de Oliveira, Fabricio Ferreira and Hu, Yan Helen and Mattke, Soeren and Merali, Zul and Monane, Mark and Sabbagh, Marwan Noel and Shobin, Eli and Weiner, Michael and Udeh-Momoh, Chinedu T.}},
  issn         = {{1552-5260}},
  keywords     = {{Alzheimer's disease; amyloid; biomarker; blood-based biomarkers; clinical implementation; clinical practice; cognitive impairment; disease-modifying treatment; patient journey; primary care; secondary care}},
  language     = {{eng}},
  number       = {{11}},
  pages        = {{8216--8224}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's and Dementia}},
  title        = {{Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease}},
  url          = {{http://dx.doi.org/10.1002/alz.14184}},
  doi          = {{10.1002/alz.14184}},
  volume       = {{20}},
  year         = {{2024}},
}